Jeffrey S. Weber, MD, PhD
Kimberly’s Concerning Mole: Exploring First-Line Treatment Strategies for Patients with Advanced Metastatic Melanoma
Kimberly’s Concerning Mole: Exploring First-Line Treatment Strategies for Pat...
Paul P. Doghramji, MD, FAAFP
Corey S. Cutler, MD, MPH, FRCPC
Doris M. Ponce, MD
Breakthroughs and Innovations: Managing Complex Cases in Graft-versus-Host Disease
Breakthroughs and Innovations: Managing Complex Cases in Graft-versus-Host Di...
Marianne J. Davies, DNP, ACNP, AOCNP
Julie R. Brahmer, MD, MSc
Addressing Barriers in Managing IRAEs Associated with Immune Checkpoint Inhibitor Therapy
Addressing Barriers in Managing IRAEs Associated with Immune Checkpoint Inhib...
Mark A. Socinski, MD
Helena Yu, MD
Keeping Pace: Advances in First-Line Therapy for EGFR-mutated NSCLC
Gilberto de Lima Lopes Junior, MD, MBA, FAMS
Kai He, MD, PhD
Jyoti D. Patel, MD, FASCO
Keeping Pace with Immunotherapy Advances in Non-Small Cell Lung Cancer: Global Lessons
Keeping Pace with Immunotherapy Advances in Non-Small Cell Lung Cancer: Globa...
William D. Tap, MD
John Healey, MD
Best Practices in the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Keeping Pace: The Use of Immunotherapy in Mutation-Positive Non-Small Cell Lung Cancer
Keeping Pace: The Use of Immunotherapy in Mutation-Positive Non-Small Cell Lu...
Ana Ferreira Castro, MD
Gilberto de Castro Junior, MD, PhD
Ricard Mesia, MD, PhD
Zujun Li, MD
Actualización sobre inmunoterapia: tratamiento de carcinoma recurrente o metastásico de células escamosas de la cabeza y el cuello
Actualización sobre inmunoterapia: tratamiento de carcinoma recurrente o meta...
Warner K. Huh, MD
Deborah K. Armstrong, MD
Robert L. Coleman, MD, FACOG, FACS
Keeping Pace in Women's Cancer: The Role of PARP Inhibitors in Ovarian Cancer
Keeping Pace with Immunotherapy Advances in Non-Small Cell Lung Cancer: Global Perspectives
Suresh S. Ramalingam, MD
Keeping Pace: The Role of Immunotherapy in the Frontline Setting
Javier Cortes, MD, PhD
Giuseppe Curigliano, MD, PhD
Peter Schmid, FRCP, MD, PhD
Real-World Evidence and Clinical Decision-Making for HR-positive/HER2-negative Metastatic Breast Cancer
Real-World Evidence and Clinical Decision-Making for HR-positive/HER2-negativ...
Applying Real-World Evidence to Improve Clinical Decision-Making for Patients with HR-positive/HER2-negative Metastatic Breast Cancer
Applying Real-World Evidence to Improve Clinical Decision-Making for Patients...
Everett E. Vokes, MD
D. Ross Camidge, MD, PhD
The Changing Landscape of NSCLC: MET Inhibitors
Peter H. O'Donnell, MD
Daniel P. Petrylak, MD
Keeping Pace: Emerging Treatment Considerations in Metastatic Urothelial Cancer
Celestia S. Higano, MD
Joaquin Mateo, MD, PhD
Precision Medicine in Advanced Prostate Cancer: A Focus on PARP Inhibitors
Loading...
Stay current with the best on medical education
Learn More
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We’re glad to see you’re enjoying Global Oncology Academy…but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.
